Table 6. The univariate and multivariate analysis employed a Cox proportional hazards model.
| Clinicopathological characteristics | Univariate analysisa | Multivariate analysisb | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | HR | P value | HR (95% CI) | P value | ||
| Age (years) | ||||||
| >65 | ||||||
| ≤65 (reference) | 1.01 (0.99–1.03) | 0.01 | ||||
| Gender | ||||||
| Male | ||||||
| Female (reference) | 0.83 (0.45–1.51) | 0.19 | ||||
| Histologic types | ||||||
| Sarcomatoid MM (reference) | ||||||
| Epithelioid MM | 0.67 (0.35–1.29) | 0.23 | 0.30 | 0.22 (0.03–0.66) | 0.12 | |
| LUAD | 0.75 (0.44–1.29) | 0.28 | 0.30 | 0.17 (0.04–0.76) | 0.02 | |
| Overall stage | ||||||
| I | 0.50 | 0.01 | ||||
| II | 0.76 (0.34–1.71) | 0.28 | 0.14 | 0.13 (0.02–0.65) | 0.13 | |
| III | 1.68 (0.85–3.32) | 0.52 | 0.41 | 0.33 (0.08–1.36) | 0.05 | |
| IV (reference) | 0.43 (0.06–3.15) | 0.84 | 0.26 | 0.08 (0.01–1.01) | 0.06 | |
| PHLDAS and p53 (≤ median vs. > median) | ||||||
| PHLDA1+ cells/mm2 | ||||||
| >51.230 | 1.27 (0.74–2.17) | 0.24 | 0.38 | 0.99 (1.00–1.01) | 0.58 | |
| PHLDA2+cells/mm2 | ||||||
| >85.09 | 1.25 (0.73–2.14) | 0.23 | 0.40 | 0.98 (0.96–0.99) | 0.01 | |
| PHLDA3+cells/mm2 | ||||||
| <70.38 | 0.90 (0.57–1.69) | 0.01 | 0.96 | 1.02 (1.00–1.05) | 0.03 | |
| P53+cells/mm2 | ||||||
| >2.87 | 1.13 (0.65–1.96) | 0.12 | 0.66 | 1.00 (1.00–1.00) | 0.38 | |
a, univariate analysis was carried out without any adjustment in order to generate hazard ratios with confidence intervals for individual risk for each of the parameters on survival; b, multivariate analysis was carried out to analyze the effects of several risk parameters on survival. PHLDA, pleckstrin homology domain family A; HR, hazard ratio (β coefficient); CI, confidence interval; MM, malignant mesothelioma; LUAD, lung adenocarcinoma.